Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PLEASE!!!! Do yourself a favor and check out FUSZ ? great product, great management and taking off like a rocket (For good reason) Check out all the deals they signed in the last month.... AND this is just the beginning, Oracle deal next month, Jointly Promoted!
You have to check out FUSZ ! great product, great management and taking off like a rocket (For good reason) Check out all the deals they signed in the last month.... AND this is just the beginning, Oracle deal next month, Jointly Promoted!
Do yourself a favor today and check out FUSZ ? great product, great management and taking off like a rocket (For good reason) Check out all the deals they signed in the last month.... AND this is just the beginning, Oracle deal next month, Jointly Promoted!
Financing is part of the deal and a very important part.... And the only results you consider a results is a revenue generating deal.
Hey Petey, did you get to check out FUSZ ? great product, great management and taking off like a rocket (For good reason) Check out all the deals they signed in the last month.... AND this is just the beginning, Oracle deal next month, Jointly Promoted!
Totally agree.... Genius!!!!!
Day to load up for another big week!
There gonna be a lot of people loading up tomorrow for next weeks news, shak and interview!!! The hits keep on coming!
Couldn't agree more!
Nice, enjoy the ride and recommend to more! Pass on the gift!
We are going to have one day in the near future where we have an immediate 100% gap up at the open.... When is it going to be? I wouldn't want to be caught out in the cold when it happens!
Please provide some links or evidence to back up your assertion!
That's what I am saying, it would have to be more of a partner, like I said someone whose prime motive is the success of the company
I don't know, but these private deals are interesting, there are many possibilities and also taking into account the financiers motives, it is possible they are taking the companies best interest into account and their goal is to have the company succeed and be in a healthy state going forward (ie. both buying in the open market and through financing), If it is a partner, maybe getting the PPS up to a decent level is part of the deal??? totally guesses on my part, but things like this usually don't happen by accident. I'm sure we will find out very soon
I hope that is the case, I think it would do wonders for the PPS. Plus the burn rate is so low, that any revenue generating contract from the best of breed Or a manufacturer and they will be running positive from a cash flow standpoint and won't need to finance any more. Also another positive is that we are debt free at this point. Best of luck
This is good, should keep going up today as the MM's got blind sided yesterday and they will have to replenish their shares also.
This is my opinion, but I think the email Chuck sent with the PR says to look at it carefully. Moving up the timeline on a the prototype, and the commercial manufacturing process integration changes, the private placement, and the strong buy in in the market yesterday, makes me think they have a seriously interested manufacturer that is ready to go ASAP
I was told the financing is going to be a private placement by interested parties that want in on the technology. My guess a partner or manufacturer
Coming very soon.... Coin, you were a year too early...
Totally not true, just emailed about it, financing being done privately. Don't talk when you have no clue
Lunchtime = Trickle up time!
It's kind of ironic that the 100K on the ask is a broker called CANT.... I think its gonna be CAN pretty soon
That is part of the problem when you are dealing with the FDA on novel products, the researchers know a lot more than the reviewers do about the product, ie. something that is obvious to the researchers has to be spelled out phonetically to the reviewers....
No problem with that, but you heard nothing positive in the call last night? he explained exactly what they were going to do and when they would do it, and that was the most expeditious route. Like I mentioned before, the sensitization issue was the only thing brought up, the rest of the application was sufficient, that is a big win. There are many companies even the big well funded ones that need to go through many application attempts before having an approval.
What "article" did you see that said there would be a revers split? Thanks
Wow, someone is posting a lot today, do you have any connection with KSS? Seems like you are talking to a lot of people from the company and different gov't agencies and universities, similar to what KSS got hi buttocks spanked by Norchi for..... I love people who pretend to be robinhood on message boards, they ALWAYS have their own agenda! Just sayin, not to discredit Zip or further dampen his pessimism
Is easy to look up, check for yourself!
WOW! Looks like they only have 28K cash? This looks like a pump before a financing/dilution is going to take place. I talked to IR, they didn't deny there would be upcoming dilution
ranza doesn't even know what the share structure is, so he doesn't know much of anything, he was responding to ziptrader who talked about need for financing sometime this year, there was NO MENTION of an RS.... just another troll
Did anyone here even listen to the call last night? Norchi was very straight forward and step by step with the FDA plan going forward. They are going to do this extra trial for this small data point. The FDA had no problem with the REST OF THE TRIAL RESULTS! This is paramount!
"The agency requested further evidence that the product does not cause sensitization in humans. While we respectfully disagree that further evidence should be necessary, we are working with the agency to address their outstanding comments, and we have determined that the most expeditious path involves providing additional data."
If anyone happened to listen to the call Norchi discussed the fact that the molecules from AC% peptide are to large to be absorbed and this was proven in the animal models, hence the short trial on humans just to prove this to the FDA's satisfaction.
This is actually significant, so you are saying that Dr Norchi out and out lied in the press release and in his conversation with Dr. KSS? What did the MIT folks have to say about the status of the contract?
TIA
Monroe and Stop, agree totally, been here a long time myself, I actually think we will be seeing some significant progress in the near term, including revenue and partnerships.
If that proves to be the case, that is good in my opinion. My main concern was whether they would need to do another trial, which certainly isn't the case if they can refile by June. I think everyone new financing would be in the cards this year
For one thing, I'm not Allo, I do appreciate the links she puts up, I am not a fan of the constant speculation....
Your quote from previous post "this stock never goes up....and the 1 day out of 50 it does go up....never holds a gain."
NEVER is a strong word and simply not accurate, I bought all my shares at 1.11 or less...
How is the price staying in the same range if it never goes up and only goes down???? A PPS theory I've never encountered before? seems to defy logic......
Update next Monday, hope it is more detailed so we know if additional trial is required or if data just needs to be presented in a different way.... Looking forward to it
I believe ASAP means as soon as possible..... and implies no specific date
Based on what???
Another monthly financing announced
If you have specific questions, why are you asking them of someone on a message board? Why don't you ask IR? Their IR folks are not typical know nothings, they are doctors/researchers that are very familiar with all of the trials and data.